Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delapril/manidipine.

Paul L McCormack1, Gillian M Keating

  • 1Adis International Limited, 51 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand. demail@adis.co.nz

Drugs
|June 3, 2006
PubMed
Summary
This summary is machine-generated.

Delapril/manidipine 30 mg/10 mg effectively lowers blood pressure (BP) in patients with essential hypertension. This fixed-dose combination therapy demonstrated superior efficacy and good tolerability compared to monotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Pharmacy

Background:

  • Essential hypertension is a widespread condition requiring effective and well-tolerated treatments.
  • Fixed-dose combination therapies offer potential advantages in patient adherence and therapeutic outcomes.
  • Angiotensin-converting enzyme (ACE) inhibitors and dihydropyridine calcium-channel antagonists are established antihypertensive agents.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of a new fixed-dose combination of delapril/manidipine (30 mg/10 mg) once daily for essential hypertension.
  • To compare the antihypertensive effects of delapril/manidipine with monotherapy using individual agents.

Main Methods:

  • A dose-finding study involving 400 patients with mild to moderate hypertension.

Related Experiment Videos

  • A 12-week comparative study in patients with mild to moderate hypertension, including non-responders to monotherapy.
  • Long-term assessment of efficacy and safety over 50 weeks.

    • Main Results:

    • Delapril/manidipine 30 mg/10 mg once daily achieved significant reductions in systolic and diastolic blood pressure.
    • The combination therapy showed superior antihypertensive efficacy compared to monotherapy with delapril or manidipine.
    • Long-term treatment (50 weeks) resulted in sustained BP reduction.
    • The combination was generally well-tolerated, with a lower incidence of ankle edema compared to manidipine monotherapy.

    Conclusions:

    • Delapril/manidipine 30 mg/10 mg is an effective and well-tolerated fixed-dose combination for treating essential hypertension.
    • This combination offers a valuable therapeutic option, potentially improving adherence and outcomes.
    • The reduced incidence of ankle edema is a notable advantage over manidipine monotherapy.